Nothing Special   »   [go: up one dir, main page]

EA201591722A1 - Новые способы получения совапревира - Google Patents

Новые способы получения совапревира

Info

Publication number
EA201591722A1
EA201591722A1 EA201591722A EA201591722A EA201591722A1 EA 201591722 A1 EA201591722 A1 EA 201591722A1 EA 201591722 A EA201591722 A EA 201591722A EA 201591722 A EA201591722 A EA 201591722A EA 201591722 A1 EA201591722 A1 EA 201591722A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new methods
counterprovir
obtaining
sovaprevir
previr
Prior art date
Application number
EA201591722A
Other languages
English (en)
Inventor
Авинаш Пхадке
Акихиро Хасимото
Венкат Гадхачанда
Original Assignee
Ачиллион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ачиллион Фармасьютикалз, Инк. filed Critical Ачиллион Фармасьютикалз, Инк.
Publication of EA201591722A1 publication Critical patent/EA201591722A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Настоящее описание включает новые способы получения совапревира, включающие добавлениесоединения Е к F-1 с получением совапревира. Настоящее описание также включает интермедиаты, которые могут использоваться для получения совапревира. Настоящее описание также включает новую кристаллическую форму совапревира, форму F, и способ получения высушенного распылением аморфного совапревира из кристаллической формы F.
EA201591722A 2013-03-14 2014-03-14 Новые способы получения совапревира EA201591722A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784182P 2013-03-14 2013-03-14
PCT/US2014/028278 WO2014152928A2 (en) 2013-03-14 2014-03-14 Novel processes for producing sovaprevir

Publications (1)

Publication Number Publication Date
EA201591722A1 true EA201591722A1 (ru) 2016-02-29

Family

ID=50680160

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591722A EA201591722A1 (ru) 2013-03-14 2014-03-14 Новые способы получения совапревира

Country Status (13)

Country Link
US (2) US9115175B2 (ru)
EP (1) EP2970195B1 (ru)
JP (1) JP2016515139A (ru)
KR (1) KR20160005334A (ru)
CN (1) CN105408317A (ru)
AU (1) AU2014236502A1 (ru)
BR (1) BR112015023343A2 (ru)
CA (1) CA2905433A1 (ru)
EA (1) EA201591722A1 (ru)
IL (1) IL241287A0 (ru)
PH (1) PH12015502121A1 (ru)
SG (1) SG11201507469RA (ru)
WO (1) WO2014152928A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US7041698B2 (en) 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
PL211889B1 (pl) 2002-05-20 2012-07-31 Bristol Myers Squibb Co Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
DE602004019518D1 (de) 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MXPA05012545A (es) 2003-05-21 2006-02-08 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
UY28423A1 (es) 2003-07-18 2005-02-28 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
CN1856502A (zh) 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 抗c型肝炎病毒活性的巨环肽
JP4584260B2 (ja) 2003-10-14 2010-11-17 インターミューン・インコーポレーテッド Ｈｃｖ複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
ES2338666T3 (es) 2004-03-15 2010-05-11 Boehringer Ingelheim International Gmbh Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
CA2560897C (en) 2004-03-30 2012-06-12 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1863833B1 (en) 2005-03-08 2013-09-18 Boehringer Ingelheim International GmbH Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
CA2615921C (en) 2005-07-20 2011-09-13 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
EA019888B1 (ru) 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
JP5190364B2 (ja) 2005-09-09 2013-04-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ペプチドの調製の為の閉環メタセシス工程
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008502A1 (en) * 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN101506223B (zh) * 2006-07-13 2013-05-22 艾其林医药公司 作为病毒复制抑制剂的4-氨基-4-氧代丁酰基肽
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

Also Published As

Publication number Publication date
EP2970195A2 (en) 2016-01-20
IL241287A0 (en) 2015-11-30
US9115175B2 (en) 2015-08-25
US20150322109A1 (en) 2015-11-12
US9481708B2 (en) 2016-11-01
AU2014236502A1 (en) 2015-10-01
CA2905433A1 (en) 2014-09-25
WO2014152928A2 (en) 2014-09-25
SG11201507469RA (en) 2015-10-29
KR20160005334A (ko) 2016-01-14
EP2970195B1 (en) 2017-08-02
BR112015023343A2 (pt) 2017-07-18
PH12015502121A1 (en) 2016-01-25
WO2014152928A3 (en) 2015-01-08
JP2016515139A (ja) 2016-05-26
US20140275480A1 (en) 2014-09-18
CN105408317A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
EA201691649A1 (ru) Способ получения противогрибковых соединений
BR112015029933B8 (pt) Método de produção de tagatose
EA201691648A1 (ru) Способ получения противогрибковых соединений
MX2015013745A (es) Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano.
UA117127C2 (uk) Спосіб одержання збагаченої вуглецем біомаси
EA201591349A1 (ru) Способ получения вортиоксетина
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201592032A1 (ru) Полиморфные формы гидрохлорида нилотиниба
EA201500863A1 (ru) Состав замеса для получения неформованного огнеупорного керамического продукта, способ получения обожжённого огнеупорного керамического продукта, обожжённый огнеупорный керамический продукт и применение неформованного огнеупорного керамического продукта
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
EA201591722A1 (ru) Новые способы получения совапревира
EA201491446A1 (ru) Способы получения пиперазинового пролекарства - ингибитора прикрепления вич
EA201590116A1 (ru) Способ получения замещенных триазолопиридинов
IN2013MU03417A (ru)
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
BR112015027977A2 (pt) método para a produção de formulações de óleo, formulações de óleo, e uso das formulações de óleo
EA201591292A1 (ru) Тапентадола малеат и его кристаллические формы
ITVI20130086A1 (it) Efficiente procedimento per la preparazione di lapatinib e suoi sali mediante nuovi intermedi
IN2013MU03755A (ru)
EA201690229A1 (ru) Способ получения дронедарона и его солей